Pre-Publication Trial Results Demonstrate Safety and Effectiveness of CyberKnife Prostate Cancer Treatment

Anova Cancer Care participates in trial that confirms non-invasive CyberKnife as a safe, effective treatment

Pre-Publication Trial Results Demonstrate Safety and Effectiveness of CyberKnife Prostate Cancer Treatment

<0> Armada Medical Marketing for Anova Cancer CareDan Snyders, 303-623-1190 x230 </0>

Pre-publication results from a national clinical trial show that prostate cancer treatment with robotic radiosurgery demonstrated excellent preservation of sexual health and resulted in no significant side effects or complications.

“This is great news for men in the Denver metro area and around the nation seeking a non-invasive alternative to surgery, radioactive seed implant or traditional radiation therapy treatments,” said Medical Director and Chief Radiosurgeon Gregg Dickerson, M.D., F.A.C.R. “These results are highly encouraging, and we’re looking forward to their publication.”

The results presented at the recent ™ 2013 Scientific Meeting represent the first Medicare-mandated annual report for the (RPCR) trial. RPCR is a long-term, prospective, observational study involving 37 community and academic institutions in 15 states. The ongoing study examined overall survival and quality of life for men treated with (SBRT) using the CyberKnife robotic surgery platform.

The RPCR trial currently includes more than 1,300 patients diagnosed with early- to intermediate-risk prostate cancer, and Anova Cancer Care is one of the leading CyberKnife centers from around the nation participating in the trial.

“Several factors make this study particularly important,” Dickerson said. “It is multi-institutional, has enrolled large numbers of patients, and is demonstrating the long-term safety and efficacy of robotic SBRT for prostate cancer.”

Dickerson has enrolled more than 320 patients in the registry, the largest number of patients contributed to the RPCR registry by a single physician. RPCR early outcome data show:

1. Excellent and durable biochemical response to treatment

2. The local control of disease is equal to any other treatment modality

3. No significant side effects or complications are occurring after treatment

4. Greater than 80% preservation of erectile function

5. Men are very satisfied with this form of treatment

Researchers reported excellent preservation of sexual health and little in the way of any late urinary problems or bowel toxicity. Post-procedure PSA scores were comparable to other forms of treatment.

Anova Cancer Care is also currently participating in a landmark comparing CyberKnife to several other types of treatment. Results are expected in 2014.

Since 2001, CyberKnife clinics nationwide have successfully treated more than 100,000 patients, and Anova Cancer Care was among the first to start treating prostate patients in Colorado. Dickerson recently assisted in the effort to educate Medicare to gain recognition of CyberKnife as a covered treatment option for prostate cancer in the four-state region that includes Colorado. As of April 2013, Anova Cancer Care has treated more than 400 men for prostate cancer with CyberKnife SBRT.

For more information, visit or call 303-396-1419. Anova Cancer Care is on Facebook at and on Twitter as .

Suggested Articles

The profit margins and management of Community Health Group raise questions about oversight of managed care insurers.

Financial experts are warning practices about the pitfalls of promoting medical credit cards to their patients.

A proposed rule issued by HHS on Tuesday would expand short-term coverage, a move Seema Verma said will have "virtually no impact" on ACA premiums.